Selected research
Industry Research
Neuraminidase Inhibitors Drug Industry Research Report 2026
Market perspective
The global Neuraminidase Inhibitors Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Neuraminidase Inhibitors Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Neuraminidase Inhibitors Drug market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Neuraminidase Inhibitors Drug market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Neuraminidase Inhibitors Drug include Teva, Roche, Pfizer, GSK, AstraZeneca, Sun Pharmaceutical, Gilead Sciences, Daiichi Sankyo and Bristol-Myers Squibb. among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Neuraminidase Inhibitors Drug market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Neuraminidase Inhibitors Drug.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Neuraminidase Inhibitors Drug Market by Company
Teva
Roche
Pfizer
GSK
AstraZeneca
Sun Pharmaceutical
Gilead Sciences
Daiichi Sankyo
Bristol-Myers Squibb
Neuraminidase Inhibitors Drug Segment by Type
Oseltamivir
Laninamivir
Peramivir
Zanamivir
Neuraminidase Inhibitors Drug Segment by Application
Hospital Pharmacy
Online Pharmacy
Retail Pharmacy
Others
Neuraminidase Inhibitors Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neuraminidase Inhibitors Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Neuraminidase Inhibitors Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neuraminidase Inhibitors Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Neuraminidase Inhibitors Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Oseltamivir
- Laninamivir
- Peramivir
- Zanamivir
Applications
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
- Others
Companies covered
- Teva
- Roche
- Pfizer
- GSK
- AstraZeneca
- Sun Pharmaceutical
- Gilead Sciences
- Daiichi Sankyo
- Bristol-Myers Squibb
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Neuraminidase Inhibitors Drug by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Oseltamivir
- 2.2.3 Laninamivir
- 2.2.4 Peramivir
- 2.2.5 Zanamivir
- 2.3 Neuraminidase Inhibitors Drug by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospital Pharmacy
- 2.3.3 Online Pharmacy
- 2.3.4 Retail Pharmacy
- 2.3.5 Others
- 2.4 Assumptions and Limitations
3 Neuraminidase Inhibitors Drug Breakdown Data by Type
- 3.1 Global Neuraminidase Inhibitors Drug Historic Market Size by Type (2021-2026)
- 3.2 Global Neuraminidase Inhibitors Drug Forecasted Market Size by Type (2027-2032)
4 Neuraminidase Inhibitors Drug Breakdown Data by Application
- 4.1 Global Neuraminidase Inhibitors Drug Historic Market Size by Application (2021-2026)
- 4.2 Global Neuraminidase Inhibitors Drug Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Neuraminidase Inhibitors Drug Market Perspective (2021-2032)
- 5.2 Global Neuraminidase Inhibitors Drug Growth Trends by Region
- 5.2.1 Global Neuraminidase Inhibitors Drug Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Neuraminidase Inhibitors Drug Historic Market Size by Region (2021-2026)
- 5.2.3 Neuraminidase Inhibitors Drug Forecasted Market Size by Region (2027-2032)
- 5.3 Neuraminidase Inhibitors Drug Market Dynamics
- 5.3.1 Neuraminidase Inhibitors Drug Industry Trends
- 5.3.2 Neuraminidase Inhibitors Drug Market Drivers
- 5.3.3 Neuraminidase Inhibitors Drug Market Challenges
- 5.3.4 Neuraminidase Inhibitors Drug Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Neuraminidase Inhibitors Drug Players by Revenue
- 6.1.1 Global Top Neuraminidase Inhibitors Drug Players by Revenue (2021-2026)
- 6.1.2 Global Neuraminidase Inhibitors Drug Revenue Market Share by Players (2021-2026)
- 6.2 Global Neuraminidase Inhibitors Drug Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Neuraminidase Inhibitors Drug Head Office and Area Served
- 6.4 Global Neuraminidase Inhibitors Drug Players, Product Type & Application
- 6.5 Global Neuraminidase Inhibitors Drug Manufacturers Established Date
- 6.6 Global Neuraminidase Inhibitors Drug Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Neuraminidase Inhibitors Drug Market Size (2021-2032)
- 7.2 North America Neuraminidase Inhibitors Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Neuraminidase Inhibitors Drug Market Size by Country (2021-2026)
- 7.4 North America Neuraminidase Inhibitors Drug Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Neuraminidase Inhibitors Drug Market Size (2021-2032)
- 8.2 Europe Neuraminidase Inhibitors Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Neuraminidase Inhibitors Drug Market Size by Country (2021-2026)
- 8.4 Europe Neuraminidase Inhibitors Drug Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Neuraminidase Inhibitors Drug Market Size (2021-2032)
- 9.2 Asia-Pacific Neuraminidase Inhibitors Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Neuraminidase Inhibitors Drug Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Neuraminidase Inhibitors Drug Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Neuraminidase Inhibitors Drug Market Size (2021-2032)
- 10.2 South America Neuraminidase Inhibitors Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Neuraminidase Inhibitors Drug Market Size by Country (2021-2026)
- 10.4 South America Neuraminidase Inhibitors Drug Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Neuraminidase Inhibitors Drug Market Size (2021-2032)
- 11.2 Middle East & Africa Neuraminidase Inhibitors Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Teva
- 12.1.1 Teva Company Information
- 12.1.2 Teva Business Overview
- 12.1.3 Teva Revenue in Neuraminidase Inhibitors Drug Business (2021-2026)
- 12.1.4 Teva Neuraminidase Inhibitors Drug Product Portfolio
- 12.1.5 Teva Recent Developments
- 12.2 Roche
- 12.2.1 Roche Company Information
- 12.2.2 Roche Business Overview
- 12.2.3 Roche Revenue in Neuraminidase Inhibitors Drug Business (2021-2026)
- 12.2.4 Roche Neuraminidase Inhibitors Drug Product Portfolio
- 12.2.5 Roche Recent Developments
- 12.3 Pfizer
- 12.3.1 Pfizer Company Information
- 12.3.2 Pfizer Business Overview
- 12.3.3 Pfizer Revenue in Neuraminidase Inhibitors Drug Business (2021-2026)
- 12.3.4 Pfizer Neuraminidase Inhibitors Drug Product Portfolio
- 12.3.5 Pfizer Recent Developments
- 12.4 GSK
- 12.4.1 GSK Company Information
- 12.4.2 GSK Business Overview
- 12.4.3 GSK Revenue in Neuraminidase Inhibitors Drug Business (2021-2026)
- 12.4.4 GSK Neuraminidase Inhibitors Drug Product Portfolio
- 12.4.5 GSK Recent Developments
- 12.5 AstraZeneca
- 12.5.1 AstraZeneca Company Information
- 12.5.2 AstraZeneca Business Overview
- 12.5.3 AstraZeneca Revenue in Neuraminidase Inhibitors Drug Business (2021-2026)
- 12.5.4 AstraZeneca Neuraminidase Inhibitors Drug Product Portfolio
- 12.5.5 AstraZeneca Recent Developments
- 12.6 Sun Pharmaceutical
- 12.6.1 Sun Pharmaceutical Company Information
- 12.6.2 Sun Pharmaceutical Business Overview
- 12.6.3 Sun Pharmaceutical Revenue in Neuraminidase Inhibitors Drug Business (2021-2026)
- 12.6.4 Sun Pharmaceutical Neuraminidase Inhibitors Drug Product Portfolio
- 12.6.5 Sun Pharmaceutical Recent Developments
- 12.7 Gilead Sciences
- 12.7.1 Gilead Sciences Company Information
- 12.7.2 Gilead Sciences Business Overview
- 12.7.3 Gilead Sciences Revenue in Neuraminidase Inhibitors Drug Business (2021-2026)
- 12.7.4 Gilead Sciences Neuraminidase Inhibitors Drug Product Portfolio
- 12.7.5 Gilead Sciences Recent Developments
- 12.8 Daiichi Sankyo
- 12.8.1 Daiichi Sankyo Company Information
- 12.8.2 Daiichi Sankyo Business Overview
- 12.8.3 Daiichi Sankyo Revenue in Neuraminidase Inhibitors Drug Business (2021-2026)
- 12.8.4 Daiichi Sankyo Neuraminidase Inhibitors Drug Product Portfolio
- 12.8.5 Daiichi Sankyo Recent Developments
- 12.9 Bristol-Myers Squibb
- 12.9.1 Bristol-Myers Squibb Company Information
- 12.9.2 Bristol-Myers Squibb Business Overview
- 12.9.3 Bristol-Myers Squibb Revenue in Neuraminidase Inhibitors Drug Business (2021-2026)
- 12.9.4 Bristol-Myers Squibb Neuraminidase Inhibitors Drug Product Portfolio
- 12.9.5 Bristol-Myers Squibb Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst